

09-210-02

1642

EXPRESS MAIL NO. EV 170136731US

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number



TRANSMITTAL FORM (To be used for all correspondence after initial filing)	Application Number	09/744,866
	Filing Date	April 2, 2001
	First Named Inventor	Frank Austrup
	Group Art Unit	1642
	Examiner Name	Stephen L. Rawlings
	Attorney Docket No.	790076.403USPC

REC'D

SEP 12 2001

TECH CENTER

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> CD(s), Number of CD(s) _____
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input checked="" type="checkbox"/> Amendment/Response	<input type="checkbox"/> Request for Corrected Filing Receipt	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> After Final	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address	<input checked="" type="checkbox"/> Return Receipt Postcard
<input type="checkbox"/> Information Disclosure Statement; Form PTO-1449	<input type="checkbox"/> Declaration	<input type="checkbox"/> Additional Enclosure(s) (please identify below): _____ _____ _____
<input type="checkbox"/> Cited References	<input type="checkbox"/> Statement under 37 CFR 3.73(b)	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Request for Refund	
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Individual Name	Stephen J. Rosenman, Ph.D.	 00500 PATENT TRADEMARK OFFICE
Signature		
Date	September 9, 2002	



EXPRESS MAIL NO EV 170136731US

PATENT # 11

RECEIVED

SEP 12 2002 7/4/02

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Frank Austrup and Michael Giesing
Application No. : 09/744,866
Filed : April 2, 2001
For : CANCER CELLS FROM BODY FLUIDS CONTAINING CELLS,
ISOLATION THEREOF AND AGENTS CONTAINING THE
SAME

Examiner : Stephen L. Rawlings
Art Unit : 1642
Docket No. : 790076.403USPC
Date : September 9, 2002

Commissioner for Patents
Washington, DC 20231

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents:

In response to the Restriction Requirement dated August 7, 2002, applicants hereby elect with traverse Group I, claims 1-7 and 10, for examination at this time.

In view of the above election, applicant hereby request that claims 8 and 9 and claims 11-21 be withdrawn without prejudice to the filing of any divisional, continuation, or continuation-in-part application. Additionally, although moot in view of the instant election, applicants reserve the right to traverse in such future applications the restriction of the application into the inventions of Group II (claim 8) and Group III (claim 9). Consideration of the Remarks submitted herewith and of the elected claims is now requested.

REMARKS

Claims 1-21 are currently pending. Applicants hereby elect Group I (claims 1-7 and 10), with traverse, as discussed in greater detail below, and request withdrawal of claims 8, 9